Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference

Detailed phenotyping is required to deepen our understanding of the biological mechanisms behind genetic associations. In addition, the impact of potentially modifiable risk factors on disease requires analytical frameworks that allow causal inference. Here, we discuss the characteristics of Recall-by-Genotype (RbG) as a study design aimed at addressing both these needs. We describe two broad scenarios for the application of RbG: studies using single variants and those using multiple variants. We consider the efficacy and practicality of the RbG approach, provide a catalogue of UK-based resources for such studies and present an online RbG study planner.Recall-by-Genotype (RbG) is an approach to recall participants from genetic studies based on their specific genotype for further, more extensive phenotyping. Here, the authors discuss examples of RbG as well as practical and ethical considerations and provide an online tool to aid in designing RbG studies.

[1]  Silja Martikainen,et al.  Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. , 2016, Cell metabolism.

[2]  Matthew Hardy,et al.  Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource , 2009, Nature Genetics.

[3]  Eric J Topol,et al.  Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials , 2010, Journal of biopharmaceutical statistics.

[4]  Jeremy Sugarman,et al.  Ethical issues in identifying and recruiting participants for familial genetic research , 2004, American journal of medical genetics. Part A.

[5]  Ethan M. Shevach,et al.  Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function , 2004, The Journal of Immunology.

[6]  B. Wilfond,et al.  Research Participants' Perspectives on Genotype-Driven Research Recruitment , 2011, Journal of empirical research on human research ethics : JERHRE.

[7]  Bartha Maria Knoppers,et al.  Genotype-driven recruitment: a strategy whose time has come? , 2013, BMC Medical Genomics.

[8]  C. Palmer,et al.  Variants of the peroxisome proliferator-activated receptor γ- and β-adrenergic receptor genes are associated with measures of compensatory eating behaviors in young children , 2007 .

[9]  Li Li,et al.  The benefits of using genetic information to design prevention trials. , 2013, American journal of human genetics.

[10]  Stephanie M. Fullerton,et al.  Recommendations for ethical approaches to genotype-driven research recruitment , 2012, Human Genetics.

[11]  G. Davey Smith,et al.  Mendelian randomization: genetic anchors for causal inference in epidemiological studies , 2014, Human molecular genetics.

[12]  J. Meigs.  The Genetic Epidemiology of Type 2 Diabetes: Opportunities for Health Translation , 2019, Current Diabetes Reports.

[13]  S. Omholt,et al.  Phenomics: the next challenge , 2010, Nature Reviews Genetics.

[14]  Marcus R Munafò,et al.  A recall-by-genotype study of CHRNA5-A3-B4 genotype, cotinine and smoking topography: study protocol , 2014, BMC Medical Genetics.

[15]  Francesco Muntoni,et al.  Managing clinically significant findings in research: the UK10K example , 2014, European Journal of Human Genetics.

[16]  Amy L McGuire,et al.  Don't throw the baby out with the bathwater: enabling a bottom-up approach in genome-wide association studies. , 2008, Genome research.

[17]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[18]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[19]  A. Hingorani,et al.  Nature's randomised trials , 2005, The Lancet.

[20]  R Garrett Morgan,et al.  Network Mendelian Randomization Study Design to Assess Factors Mediating the Causal Link Between Telomere Length and Heart Disease. , 2017, Circulation research.

[21]  Steven A Goldstein,et al.  Variable Bone Fragility Associated With an Amish COL1A2 Variant and a Knock-in Mouse Model , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  D. Lawlor,et al.  Assessing the Causal Role of Body Mass Index on Cardiovascular Health in Young Adults , 2017, bioRxiv.

[23]  Asher Mullard,et al.  Calls grow to tap the gold mine of human genetic knockouts , 2017, Nature Reviews Drug Discovery.

[24]  Paul C. Fletcher,et al.  Divergent effects of central melanocortin signalling on fat and sucrose preference in humans , 2016, Nature Communications.

[25]  G. Davey Smith,et al.  Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression , 2015, International journal of epidemiology.

[26]  Alan R. Shuldiner,et al.  The ABCG8 G574R Variant, Serum Plant Sterol Levels, and Cardiovascular Disease Risk in the Old Order Amish , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[27]  Tony R. Merriman,et al.  Insight into rheumatological cause and effect through the use of Mendelian randomization , 2016, Nature Reviews Rheumatology.

[28]  David B Goldstein,et al.  Ethical challenges in genotype-driven research recruitment. , 2010, Genome research.

[29]  Mark Atkinson,et al.  Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes , 2007, Nature Genetics.

[30]  Peter Kraft,et al.  Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. , 2015, American journal of human genetics.

[31]  Colin N A Palmer,et al.  Tailored second-line therapy in asthmatic children with the Arg(16) genotype. , 2013, Clinical science.

[32]  Stephen Burgess,et al.  Mendelian randomization: where are we now and where are we going? , 2015, International journal of epidemiology.

[33]  Alan R. Shuldiner,et al.  Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish , 2014, Diabetologia.

[34]  M. McCarthy,et al.  Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.

[35]  Adrian P Mander,et al.  Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial , 2016, PLoS medicine.

[36]  Hanieh Yaghootkar,et al.  Functional characterisation of ADIPOQ variants using individuals recruited by genotype , 2016, Molecular and Cellular Endocrinology.

[37]  Nicholas J. Timpson,et al.  Genetics, sleep and memory: a recall-by-genotype study of ZNF804A variants and sleep neurophysiology , 2015, BMC Medical Genetics.

[38]  Daniel G. MacArthur,et al.  Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity , 2017, Nature.

[39]  Sarah E. Medland,et al.  Mining the Human Phenome Using Allelic Scores That Index Biological Intermediates , 2013, PLoS genetics.

[40]  R. Collins.  What makes UK Biobank special? , 2012, The Lancet.

[41]  Mattias Ohlsson,et al.  Statistical power considerations in genotype-based recall randomized controlled trials , 2016, Scientific Reports.

[42]  P. Visscher,et al.  Common SNPs explain a large proportion of heritability for human height , 2011 .

[43]  James T. Elder,et al.  Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study , 2016, PLoS medicine.

[44]  Peter M Visscher,et al.  Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. , 2009, Human molecular genetics.

[45]  George Davey Smith,et al.  Using multiple genetic variants as instrumental variables for modifiable risk factors , 2012, Statistical methods in medical research.

[46]  Nicholas Timpson,et al.  The ethics conundrum in Recall by Genotype (RbG) research: Perspectives from birth cohort participants , 2017, bioRxiv.

[47]  D. Altshuler,et al.  Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.

[48]  S. Schulz,et al.  ADORA2A genotype modulates interoceptive and exteroceptive processing in a fronto-insular network , 2016, European Neuropsychopharmacology.

[49]  Pak Chung Sham,et al.  GWASdb: a database for human genetic variants identified by genome-wide association studies , 2011, Nucleic Acids Res..

[50]  Jeffrey R O'Connell,et al.  Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. , 2014, The New England journal of medicine.

[51]  B. Wilfond,et al.  Disclosing Individual Genetic Results to Research Participants , 2006, The American journal of bioethics : AJOB.

[52]  Christopher E Brightling,et al.  Cohort Profile Cohort Profile : Extended Cohort for E-health , Environment and DNA ( EXCEED ) , 2019 .

[53]  F. Karpe,et al.  The in vivo effects of the Pro12Ala PPARγ2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank , 2005, Diabetologia.

[54]  Linda S. Wicker,et al.  Type 1 Diabetes-Associated IL2RA Variation Lowers IL-2 Signaling and Contributes to Diminished CD4+CD25+ Regulatory T Cell Function , 2012, The Journal of Immunology.

[55]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[56]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[57]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[58]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[59]  R. Simon,et al.  On the efficiency of targeted clinical trials , 2005, Statistics in medicine.